Results for tag: "PD L1 Inhibitor"

The PD-L1 inhibitor market is a subset of the larger immune disorder drugs market. PD-L1 inhibitors are a type of immunotherapy drug used to treat a variety of cancers and other immune-related diseases. These drugs work by blocking the interaction between PD-L1, a protein found on the surface of cancer cells, and its receptor, PD-1, which is found on the surface of immune cells. By blocking this interaction, PD-L1 inhibitors can help the immune system recognize and attack cancer cells. PD-L1 inhibitors are a relatively new class of drugs, but they have already shown promise in treating a variety of cancers, including lung, bladder, and head and neck cancers. They are also being studied for their potential to treat other immune-related diseases, such as rheumatoid arthritis and multiple sclerosis. Some of the companies in the PD-L1 inhibitor market include Merck, Bristol-Myers Squibb, AstraZeneca, Roche, and Pfizer. These companies are actively researching and developing PD-L1 inhibitors for the treatment of various cancers and other immune-related diseases. Show Less Read more